They lost less money per share than expected, which is something. Sixty-four cents, instead of the predicted dollar oh three. Good for them. Revenue, though, was down. Four point seven percent. Two hundred forty million, two hundred oh five, it’s all just numbers, really. The Street wanted two forty-three point seven million. Humans always want more. So it goes.
The filings with the Securities and Exchange Commission reveal this addition to their holdings, bringing the total value of their ServiceTitan investment to $24.11 million – a rise of $9.42 million. A substantial sum, to be sure, but in the grand theatre of capital, merely a prologue to a more ambitious performance.
The market, predictably, has reacted with a degree of pessimism. The stock price reflects this unease. However, such downturns often present opportunities for those willing to look beyond the immediate headlines. The question, as always, is whether the price adequately reflects the underlying realities.
It appears HHLR, a firm not entirely unfamiliar with the art of speculation, had allowed Baidu to constitute a rather robust 5.3% of their Assets Under Management. A rather large slice of the pie, one might observe, to dedicate to a Chinese internet concern. One wonders if the initial enthusiasm stemmed from a genuine belief in Baidu’s potential, or merely a fleeting infatuation with the exotic allure of the Far East. The market, as always, provides the ultimate, and usually brutal, assessment.
Let’s get down to brass tacks. Exelixis isn’t reinventing the wheel, they’re refining it. Cabometyx, their flagship drug, is a cancer treatment. Sounds mundane, doesn’t it? But this isn’t about saving the world; it’s about capturing market share in a brutal, unforgiving landscape. They’ve carved out a niche in renal cell carcinoma, and they’re not afraid to expand. They’re playing the combo game, partnering with the big boys like Bristol Myers Squibb and their Opdivo franchise. Smart. Cynical. Effective. Revenue, earnings, free cash flow – all trending UP. The S&P 500? They’ve nudged past it. It’s not a rocket launch, but it’s a sustained climb. And in this business, sustained is everything.
The Daventry Group’s filing with the Securities and Exchange Commission confirms the purchase of these shares during the final quarter of 2025. The $11.03 million figure represents the value of the shares as of that date. It is a simple fact, yet one often obscured by the noise of market speculation.
The SEC filings, those bureaucratic chronicles of capital flows, confirm the complete abandonment of SentinelOne by Daventry. The net effect? A $6.48 million subtraction from the portfolio, a sum that, while substantial, hardly signals a crisis. It’s more akin to a seasoned gambler cashing out a portion of their winnings – a pragmatic decision, not a panicked retreat. The fund now reports a stake of precisely zero, a statement of fact as stark and unambiguous as a winter frost.
The current market cap? Three point seven trillion. Not small change. Getting to six in four years means a twelve-and-a-half percent annual growth rate. Ambitious? Yes. Impossible? Not in this market. It’s a climb, but one within reach, if the cards fall right.
Five designated equities present themselves as potential conduits for this anticipated flow. Each, save one, bears the visible marks of recent disfavor, a temporary misalignment with the prevailing currents. The allocation of capital, even in seemingly arbitrary amounts, may prove… satisfactory. Or not. The system offers no guarantees.
Now, Genpact itself is a concern engaged in the rather modern business of business process outsourcing, and all that. They handle the fiddly bits for other companies – the finance, the supply chains, the IT, the digital transformations – leaving their clients free to concentrate on the really important things, like deciding what colour the stationery should be. They’ve been doing rather well, actually, turning over a respectable $5.08 billion last year and netting a profit of $552.49 million. Not to be sneezed at, what!